ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $293,679 | -26.1% | 14,640 | +4.0% | 0.00% | – |
| Q2 2023 | $397,225 | +71.3% | 14,081 | +4.5% | 0.00% | – |
| Q1 2023 | $231,821 | -20.1% | 13,478 | -6.4% | 0.00% | – |
| Q4 2022 | $290,016 | +12.8% | 14,400 | +21.1% | 0.00% | – |
| Q3 2022 | $257,000 | -16.0% | 11,891 | +9.3% | 0.00% | – |
| Q2 2022 | $306,000 | -44.1% | 10,880 | -8.3% | 0.00% | – |
| Q1 2022 | $547,000 | -43.7% | 11,862 | +2.6% | 0.00% | -100.0% |
| Q4 2021 | $972,000 | -7.9% | 11,559 | -27.0% | 0.00% | 0.0% |
| Q3 2021 | $1,055,000 | +34.9% | 15,831 | +7.8% | 0.00% | 0.0% |
| Q2 2021 | $782,000 | +205.5% | 14,691 | +148.5% | 0.00% | – |
| Q1 2021 | $256,000 | -28.9% | 5,911 | -14.7% | 0.00% | – |
| Q4 2020 | $360,000 | – | 6,932 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |